Beauty Farm Medical and Health Industry Inc. disclosed that it repurchased 7,000 ordinary shares on 13 April 2026 via on-market transactions at The Stock Exchange of Hong Kong, paying an aggregate HK$0.14 million. The purchase price ranged between HK$19.95 and HK$20.68 per share, with a volume-weighted average cost of HK$20.11.

Following the repurchase, the company’s outstanding share count (excluding treasury shares) decreased marginally to 250.17 million, while treasury shares rose to 1.43 million—equivalent to approximately 0.57 % of the total 251.59 million issued shares.

The buyback forms part of the mandate granted at the 27 June 2025 shareholders’ meeting, which authorises the company to repurchase up to 23.58 million shares. Cumulative repurchases under this mandate now stand at 1.43 million shares, representing about 0.60 % of the shares in issue on the mandate’s adoption date.

In line with Hong Kong listing rules, Beauty Farm is subject to a moratorium on new share issues or treasury-share sales until 13 May 2026.